LTC2924034I2 - Farmacinė kompozicija, apimanti nenukleozidinį atvirkštinės transkriptazės inhibitorių - Google Patents

Farmacinė kompozicija, apimanti nenukleozidinį atvirkštinės transkriptazės inhibitorių

Info

Publication number: LTC2924034I2
Authority: LT; Lithuania
Prior art keywords: pharmaceutical composition; reverse transcriptase; nucleoside reverse; transcriptase inhibitor; nucleoside
Prior art date: 2010-03-30

Application number

LTPA2019507C

Other languages

English (en)

Original Assignee

Merck Canada Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-03-30

Filing date

2019-04-11

Publication date

2020-10-12

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44710363&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LTC2924034(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2019-04-11 Application filed by Merck Canada Inc. filed Critical Merck Canada Inc.

2019-04-25 Publication of LTPA2019507I1 publication Critical patent/LTPA2019507I1/lt

2020-10-12 Publication of LTC2924034I2 publication Critical patent/LTC2924034I2/lt

Links

229940042402 non-nucleoside reverse transcriptase inhibitor Drugs 0.000 title 1
239000002726 nonnucleoside reverse transcriptase inhibitor Substances 0.000 title 1
239000008194 pharmaceutical composition Substances 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Communicable Diseases (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Oncology (AREA)
Virology (AREA)
Tropical Medicine & Parasitology (AREA)
Molecular Biology (AREA)
AIDS & HIV (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Steroid Compounds (AREA)
Saccharide Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

LTPA2019507C 2010-03-30 2019-04-11 Farmacinė kompozicija, apimanti nenukleozidinį atvirkštinės transkriptazės inhibitorių LTC2924034I2 (lt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US31882410P	2010-03-30	2010-03-30
US32157310P	2010-04-07	2010-04-07
EP11761856.1A EP2552902B1 (en)	2010-03-30	2011-03-28	Non-nucleoside reverse transcriptase inhibitors

Publications (2)

Publication Number	Publication Date
LTPA2019507I1 LTPA2019507I1 (lt)	2019-04-25
LTC2924034I2 true LTC2924034I2 (lt)	2020-10-12

Family

ID=44710363

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
LTEP15157348.2T LT2924034T (lt)	2010-03-30	2011-03-28	Farmacinė kompozicija, apimanti nenukleozidinį atvirkštinės transkriptazės inhibitorių
LTPA2019507C LTC2924034I2 (lt)	2010-03-30	2019-04-11	Farmacinė kompozicija, apimanti nenukleozidinį atvirkštinės transkriptazės inhibitorių
LTPA2019506 LTC2552902I2 (lt)	2010-03-30	2019-04-11	Nenukleozidinės reversinės transkriptazės inhibitoriai

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
LTEP15157348.2T LT2924034T (lt)	2010-03-30	2011-03-28	Farmacinė kompozicija, apimanti nenukleozidinį atvirkštinės transkriptazės inhibitorių

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
LTPA2019506 LTC2552902I2 (lt)	2010-03-30	2019-04-11	Nenukleozidinės reversinės transkriptazės inhibitoriai

Country Status (44)

Country	Link
US (2)	US8486975B2 (lt)
EP (2)	EP2924034B1 (lt)
JP (2)	JP5281718B2 (lt)
KR (1)	KR101421861B1 (lt)
CN (1)	CN102971308B (lt)
AR (1)	AR080859A1 (lt)
AU (1)	AU2011235568B2 (lt)
BR (1)	BR112012024691B1 (lt)
CA (1)	CA2794377C (lt)
CL (1)	CL2012002744A1 (lt)
CO (1)	CO6630126A2 (lt)
CR (1)	CR20120503A (lt)
CY (3)	CY1118774T1 (lt)
DK (2)	DK2924034T3 (lt)
DO (1)	DOP2012000256A (lt)
EA (1)	EA024804B1 (lt)
EC (1)	ECSP12012201A (lt)
ES (2)	ES2609636T3 (lt)
FI (1)	FIC20190021I1 (lt)
GE (1)	GEP20156368B (lt)
HN (1)	HN2012002039A (lt)
HR (2)	HRP20150427T1 (lt)
HU (4)	HUE025336T2 (lt)
IL (2)	IL222030A (lt)
LT (3)	LT2924034T (lt)
LU (2)	LUC00114I2 (lt)
MA (1)	MA34170B1 (lt)
ME (2)	ME02570B (lt)
MX (1)	MX2012011379A (lt)
MY (1)	MY163979A (lt)
NI (1)	NI201200146A (lt)
NL (1)	NL300980I2 (lt)
NO (2)	NO2019019I1 (lt)
NZ (1)	NZ602670A (lt)
PE (1)	PE20130158A1 (lt)
PH (1)	PH12012501923A1 (lt)
PL (2)	PL2924034T3 (lt)
PT (2)	PT2924034T (lt)
RS (2)	RS55505B1 (lt)
SG (1)	SG184347A1 (lt)
SI (2)	SI2924034T1 (lt)
TN (1)	TN2012000455A1 (lt)
TW (1)	TWI458719B (lt)
WO (1)	WO2011120133A1 (lt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MX2012011379A (es) *	2010-03-30	2012-11-30	Merck Canada Inc	Inhibidores no nucleosidicos de la transcriptasa inversa.
WO2012048113A2 (en)	2010-10-07	2012-04-12	The General Hospital Corporation	Biomarkers of cancer
EP2900240B1 (en) *	2012-09-26	2020-01-08	Merck Sharp & Dohme Corp.	Crystalline form of a reverse transcriptase inhibitor
JO3470B1 (ar)	2012-10-08	2020-07-05	Merck Sharp & Dohme	مشتقات 5- فينوكسي-3h-بيريميدين-4-أون واستخدامها كمثبطات ناسخ عكسي ل hiv
CN104994855B (zh) *	2012-12-05	2018-06-05	默沙东公司	制备逆转录酶抑制剂的方法
EP3071037A4 (en) *	2013-11-22	2017-08-02	Merck Sharp & Dohme Corp.	Composition of a non-nucleoside reverse transcriptase inhibitor
KR101803671B1 (ko) *	2013-12-04	2017-11-30	머크 샤프 앤드 돔 코포레이션	역전사효소 억제제의 제조 방법
SI3125894T1 (sl)	2014-04-01	2020-12-31	Merck Sharp & Dohme Corp.	Predzdravila inhibitorjev reverzne transkriptaze HIV
EP3161159B1 (en)	2014-06-25	2020-08-05	The General Hospital Corporation	Targeting human satellite ii (hsatii)
RU2736941C2 (ru)	2015-12-02	2020-11-23	Мерк Шарп энд Доум Корп.	Фармацевтические композиции, содержащие доравирин, тенофовира дизопроксила фумарат и ламивудин
WO2018175271A1 (en) *	2017-03-24	2018-09-27	Merck Sharp & Dohme Corp.	Formulation for parenteral administration
RU2019136678A (ru)	2017-04-18	2021-05-18	Сипла Лимитед	Комбинированная терапия для применения в лечении ретровирусных инфекций
EP4317972A3 (en)	2018-02-06	2024-03-13	The General Hospital Corporation	Repeat rna as biomarkers of tumor immune response
WO2020018352A1 (en)	2018-07-17	2020-01-23	Merck Sharp & Dohme Corp.	Hiv drug combination for increasing barrier against resistance
MX2021007382A (es)	2018-12-18	2021-07-15	Merck Sharp & Dohme Llc	Derivados de pirimidona como agentes citotoxicos selectivos contra celulas infectadas por vih.
CN110801455B (zh) *	2019-11-12	2020-06-02	河北医科大学第二医院	用于治疗mrsa的药物组合物及其应用
CN114163309B (zh) *	2021-12-27	2023-04-25	甘肃皓天医药科技有限责任公司	一种多拉韦林中间体的制备方法
CN114349690B (zh) *	2022-02-15	2023-04-25	甘肃皓天医药科技有限责任公司	一种多拉韦林中间体合成方法
CN116903590A (zh) *	2023-06-06	2023-10-20	延边大学	一种含杂环结构的吡啶酮类化合物及其制备方法和用途
CN120157613A (zh) *	2023-12-15	2025-06-17	山东诚创蓝海医药科技有限公司	多拉韦林中间体及其应用和合成方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE9904045D0 (sv)	1999-11-09	1999-11-09	Astra Ab	Compounds
TW200423930A (en) *	2003-02-18	2004-11-16	Hoffmann La Roche	Non-nucleoside reverse transcriptase inhibitors
TW200505441A (en) *	2003-03-24	2005-02-16	Hoffmann La Roche	Non-nucleoside reverse transcriptase inhibitorsⅠ
WO2004085406A1 (en)	2003-03-24	2004-10-07	F. Hoffmann-La Roche Ag	Benzyl-pyridazinons as reverse transcriptase inhibitors
US7166738B2 (en)	2004-04-23	2007-01-23	Roche Palo Alto Llc	Non-nucleoside reverse transcriptase inhibitors
AU2005235692B2 (en)	2004-04-23	2011-11-10	F. Hoffmann-La Roche Ag	Non-nucleoside reverse transcriptase inhibitors
JP2008525419A (ja)	2004-12-22	2008-07-17	ファイザー・リミテッド	Ｈｉｖ−１逆転写酵素の非ヌクレオシド阻害剤
AR057455A1 (es)	2005-07-22	2007-12-05	Merck & Co Inc	Inhibidores de la transcriptasa reversa de vih y composicion farmaceutica
ES2320042T3 (es)	2005-10-19	2009-05-18	F. Hoffmann-La Roche Ag	Inhibidores de transcriptasa reversa con nucleosidos de n-fenil fenilacetamida.
EP1940781A1 (en)	2005-10-19	2008-07-09	F.Hoffmann-La Roche Ag	Phenyl-acetamide nnrt inhibitors
TW200831085A (en)	2006-12-13	2008-08-01	Merck & Co Inc	Non-nucleoside reverse transcriptase inhibitors
CN101952274A (zh)	2007-11-20	2011-01-19	默沙东公司	非核苷逆转录酶抑制剂
MX2012011379A (es) *	2010-03-30	2012-11-30	Merck Canada Inc	Inhibidores no nucleosidicos de la transcriptasa inversa.

2011
- 2011-03-28 MX MX2012011379A patent/MX2012011379A/es active IP Right Grant
- 2011-03-28 PL PL15157348T patent/PL2924034T3/pl unknown
- 2011-03-28 HU HUE11761856A patent/HUE025336T2/en unknown
- 2011-03-28 HU HUE15157348A patent/HUE031785T2/en unknown
- 2011-03-28 SI SI201131054A patent/SI2924034T1/sl unknown
- 2011-03-28 ME MEP-2016-282A patent/ME02570B/me unknown
- 2011-03-28 MA MA35324A patent/MA34170B1/fr unknown
- 2011-03-28 LT LTEP15157348.2T patent/LT2924034T/lt unknown
- 2011-03-28 ME MEP-2015-76A patent/ME02181B/me unknown
- 2011-03-28 RS RS20161093A patent/RS55505B1/sr unknown
- 2011-03-28 US US13/073,631 patent/US8486975B2/en active Active
- 2011-03-28 PL PL11761856T patent/PL2552902T3/pl unknown
- 2011-03-28 BR BR112012024691-7A patent/BR112012024691B1/pt active IP Right Grant
- 2011-03-28 EP EP15157348.2A patent/EP2924034B1/en active Active
- 2011-03-28 GE GEAP201112882A patent/GEP20156368B/en unknown
- 2011-03-28 SG SG2012072401A patent/SG184347A1/en unknown
- 2011-03-28 PE PE2012001823A patent/PE20130158A1/es active IP Right Grant
- 2011-03-28 JP JP2012538161A patent/JP5281718B2/ja active Active
- 2011-03-28 ES ES15157348.2T patent/ES2609636T3/es active Active
- 2011-03-28 MY MYPI2012004342A patent/MY163979A/en unknown
- 2011-03-28 NZ NZ602670A patent/NZ602670A/en unknown
- 2011-03-28 DK DK15157348.2T patent/DK2924034T3/en active
- 2011-03-28 PH PH1/2012/501923A patent/PH12012501923A1/en unknown
- 2011-03-28 SI SI201130491T patent/SI2552902T1/sl unknown
- 2011-03-28 WO PCT/CA2011/000320 patent/WO2011120133A1/en not_active Ceased
- 2011-03-28 DK DK11761856.1T patent/DK2552902T3/en active
- 2011-03-28 EA EA201290976A patent/EA024804B1/ru active Protection Beyond IP Right Term
- 2011-03-28 HR HRP20150427TT patent/HRP20150427T1/hr unknown
- 2011-03-28 KR KR1020127025733A patent/KR101421861B1/ko active Active
- 2011-03-28 RS RS20150340A patent/RS54017B1/sr unknown
- 2011-03-28 EP EP11761856.1A patent/EP2552902B1/en active Active
- 2011-03-28 PT PT151573482T patent/PT2924034T/pt unknown
- 2011-03-28 CA CA2794377A patent/CA2794377C/en active Active
- 2011-03-28 ES ES11761856.1T patent/ES2536295T3/es active Active
- 2011-03-28 CN CN201180018074.2A patent/CN102971308B/zh active Active
- 2011-03-28 AU AU2011235568A patent/AU2011235568B2/en active Active
- 2011-03-28 PT PT117618561T patent/PT2552902E/pt unknown
- 2011-03-29 TW TW100110833A patent/TWI458719B/zh active
- 2011-03-29 AR ARP110101028A patent/AR080859A1/es active IP Right Grant
2012
- 2012-09-20 TN TNP2012000455A patent/TN2012000455A1/en unknown
- 2012-09-20 IL IL222030A patent/IL222030A/en active Protection Beyond IP Right Term
- 2012-09-27 HN HN2012002039A patent/HN2012002039A/es unknown
- 2012-09-28 NI NI201200146A patent/NI201200146A/es unknown
- 2012-09-28 CL CL2012002744A patent/CL2012002744A1/es unknown
- 2012-09-28 DO DO2012000256A patent/DOP2012000256A/es unknown
- 2012-10-01 CR CR20120503A patent/CR20120503A/es unknown
- 2012-10-01 EC ECSP12012201 patent/ECSP12012201A/es unknown
- 2012-10-01 CO CO12171897A patent/CO6630126A2/es active IP Right Grant
2013
- 2013-05-23 JP JP2013108533A patent/JP5886790B2/ja not_active Expired - Fee Related
- 2013-07-03 US US13/934,633 patent/US20130296382A1/en not_active Abandoned
2014
- 2014-06-23 IL IL233334A patent/IL233334A/en active IP Right Grant
2016
- 2016-12-09 HR HRP20161680TT patent/HRP20161680T1/hr unknown
2017
- 2017-01-25 CY CY20171100114T patent/CY1118774T1/el unknown
2019
- 2019-04-09 HU HUS1900021C patent/HUS1900021I1/hu unknown
- 2019-04-09 HU HUS1900022C patent/HUS1900022I1/hu unknown
- 2019-04-11 LT LTPA2019507C patent/LTC2924034I2/lt unknown
- 2019-04-11 LT LTPA2019506 patent/LTC2552902I2/lt unknown
- 2019-04-16 NL NL300980C patent/NL300980I2/nl unknown
- 2019-04-17 LU LU00114C patent/LUC00114I2/fr unknown
- 2019-04-17 LU LU00113C patent/LUC00113I9/fr unknown
- 2019-04-17 FI FIC20190021C patent/FIC20190021I1/fi unknown
- 2019-04-24 NO NO2019019C patent/NO2019019I1/no unknown
- 2019-04-24 NO NO2019018C patent/NO2019018I1/no unknown
- 2019-05-16 CY CY2019025C patent/CY2019025I1/el unknown
- 2019-05-16 CY CY2019026C patent/CY2019026I2/el unknown

Also Published As

Publication number	Publication date
EA024804B1 (ru)	2016-10-31
LUC00113I9 (lt)	2024-06-07
EP2552902A1 (en)	2013-02-06
AR080859A1 (es)	2012-05-16
CY2019026I1 (el)	2020-05-29
CR20120503A (es)	2013-01-09
KR20120128703A (ko)	2012-11-27
NL300980I2 (nl)	2021-06-17
CY2019025I2 (el)	2019-11-27
IL222030A (en)	2014-07-31
US20110245296A1 (en)	2011-10-06
HUS1900022I1 (hu)	2019-05-28
KR101421861B1 (ko)	2014-07-22
CY2019025I1 (el)	2019-11-27
EA201290976A1 (ru)	2013-03-29
IL233334A (en)	2015-09-24
CO6630126A2 (es)	2013-03-01
EP2552902B1 (en)	2015-03-11
TN2012000455A1 (en)	2014-01-30
EP2924034A1 (en)	2015-09-30
NO2019018I1 (no)	2019-04-24
BR112012024691B1 (pt)	2020-11-17
GEP20156368B (en)	2015-09-25
PL2552902T3 (pl)	2015-10-30
PT2924034T (pt)	2017-01-06
LT2924034T (lt)	2016-12-27
PT2552902E (pt)	2015-06-02
HK1175471A1 (en)	2013-07-05
JP2013209405A (ja)	2013-10-10
DK2924034T3 (en)	2017-02-06
ECSP12012201A (es)	2012-10-30
HRP20161680T1 (hr)	2017-01-27
HN2012002039A (es)	2015-08-24
SI2924034T1 (sl)	2017-05-31
LTC2552902I2 (lt)	2019-12-10
SI2552902T1 (sl)	2015-10-30
CN102971308B (zh)	2015-02-04
MX2012011379A (es)	2012-11-30
AU2011235568A1 (en)	2012-11-01
SG184347A1 (en)	2012-11-29
NO2019019I1 (no)	2019-04-24
JP2013510800A (ja)	2013-03-28
HUE025336T2 (en)	2016-03-29
AU2011235568B2 (en)	2013-09-12
ES2536295T3 (es)	2015-05-22
MY163979A (en)	2017-11-15
CN102971308A (zh)	2013-03-13
TWI458719B (zh)	2014-11-01
TW201139409A (en)	2011-11-16
PH12012501923A1 (en)	2013-02-04
BR112012024691A2 (pt)	2019-07-02
CA2794377A1 (en)	2011-10-06
HUS1900021I1 (hu)	2019-05-28
LTPA2019506I1 (lt)	2019-04-25
EP2924034B1 (en)	2016-11-02
HUE031785T2 (en)	2017-08-28
HK1209121A1 (en)	2016-03-24
CA2794377C (en)	2015-06-16
PL2924034T3 (pl)	2017-07-31
LTPA2019507I1 (lt)	2019-04-25
US8486975B2 (en)	2013-07-16
JP5886790B2 (ja)	2016-03-16
NL300980I1 (nl)	2019-04-24
ME02181B (me)	2015-10-20
HRP20150427T1 (hr)	2015-07-03
RS55505B1 (sr)	2017-05-31
ES2609636T3 (es)	2017-04-21
CY1118774T1 (el)	2017-07-12
LUC00114I1 (lt)	2019-04-17
EP2552902A4 (en)	2013-09-04
ME02570B (me)	2017-06-20
DOP2012000256A (es)	2012-12-15
NZ602670A (en)	2014-09-26
FIC20190021I1 (fi)	2019-04-17
LUC00113I2 (lt)	2024-05-22
LUC00114I2 (lt)	2020-07-10
CY2019026I2 (el)	2020-05-29
PE20130158A1 (es)	2013-02-28
JP5281718B2 (ja)	2013-09-04
WO2011120133A1 (en)	2011-10-06
IL233334A0 (en)	2014-09-01
CL2012002744A1 (es)	2012-12-14
DK2552902T3 (en)	2015-06-15
MA34170B1 (fr)	2013-04-03
NI201200146A (es)	2013-03-18
RS54017B1 (sr)	2015-10-30
US20130296382A1 (en)	2013-11-07

Publication	Publication Date	Title
LTPA2019507I1 (lt)	2019-04-25	Farmacinė kompozicija, apimanti nenukleozidinį atvirkštinės transkriptazės inhibitorių
SMT201700008B (it)	2017-03-08	Composizione farmaceutica
SMT201600350B (it)	2016-11-10	Composizioni farmaceutiche
DK3192501T3 (da)	2020-08-03	Topisk farmaceutisk sammensætning baseret på semifluorerede alkaner
DK2421825T3 (da)	2014-02-03	Azetidinyldiamider som monoacylglycerollipase-inhibitorer
BR112014001255A2 (pt)	2017-02-21	composto, uso de um composto, combinação, e, composição farmacêutica
DK4374878T3 (da)	2025-05-05	Farmaceutisk sammensætning, der omfatter carbetocin
DK4159204T3 (da)	2024-05-21	Hidtil ukendt farmaceutisk sammensætning
BR112013003536A2 (pt)	2016-06-28	composição, e utilização de uma composição.
BR112014003567A2 (pt)	2018-08-14	composto, uso de um composto, e, composição farmacêutica
EP2647381A4 (en)	2015-12-23	MELTING TABLET
EE201300005A (et)	2013-08-15	Ravimkoostis
DK3070091T3 (da)	2019-07-08	Benzodioxolderivater som phosphodiesterasehæmmere
IT1401989B1 (it)	2013-08-28	Espansore rapido palatale con dentino antiritorno
CO6801722A2 (es)	2013-11-29	Composiciones farmacéuticas
BR112013019518A2 (pt)	2018-07-10	composições para cuidado oral.
EP2612657A4 (en)	2014-05-07	MELTING TABLET
BR112013019061A2 (pt)	2018-06-26	composto inibidor da caspase-2, composição farmacêutica e uso de um composto
BR112012029461A2 (pt)	2017-03-01	composição farmacêutica contendo solifenacina
BR112012029887A2 (pt)	2016-08-16	composição farmacêutica
BR112014016122A8 (pt)	2017-07-04	composto, e, composição farmacêutica
BR112013022890A2 (pt)	2016-09-13	composto, composição farmacêutica, combinação e uso de um composto
EP3071037A4 (en)	2017-08-02	Composition of a non-nucleoside reverse transcriptase inhibitor
BR112014001932A2 (pt)	2017-02-21	composto, composição farmacêutica, combinação de um composto e uso de um composto
IT1406067B1 (it)	2014-02-06	Composizioni eudermiche.